<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864838</url>
  </required_header>
  <id_info>
    <org_study_id>4429/2008</org_study_id>
    <nct_id>NCT00864838</nct_id>
  </id_info>
  <brief_title>Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab</brief_title>
  <official_title>Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of anterior chamber paracentesis,
      brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after
      intravitreal bevacizumab injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (mmHg)</measure>
    <time_frame>1 hour and, 3 minutes before IVI. 3,10,20, 30 minutes after IVI</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>250 mg 1 hour before intravitreal injection</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine tartarate</intervention_name>
    <description>1 drop 1 hour before intravitreal injection</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Alphagan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anterior chamber paracentesis</intervention_name>
    <description>Immediately after bevacizumab injection</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of age related macular disease or diabetic retinopathy

          -  Able and willing to provide informed consent

        Exclusion Criteria:

          -  History of ocular hypertension or glaucoma

          -  High Myopes (&gt; 6 spherical diopters)

          -  High Hyperopes (&gt; 4 spherical diopters)

          -  Pulmonary disease

          -  Renal disease

          -  Known allergy to any component of the study drug

          -  Myocardial infarction, transient ischemic attack within 4 months prior to
             randomization or any contraindication for bevacizumab use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Jorge, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco A Bonini-Filho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bianka Y Katayama, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinic´s Hospital, Ribeirão Preto Medical School, University of São Paulo</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <last_update_submitted>March 18, 2009</last_update_submitted>
  <last_update_submitted_qc>March 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marco Antonio Bonini Filho</name_title>
    <organization>Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo</organization>
  </responsible_party>
  <keyword>intraocular pressure</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>acetazolamide</keyword>
  <keyword>brimonidine</keyword>
  <keyword>anterior chamber paracentesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

